Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Merck Sharpe and Dohme to licence hepatitis detection technology

Merck Sharpe and Dohme to licence hepatitis detection technology

28th July 2010

Merck Sharpe and Dohme has agreed a new licensing deal which will allow for the development of a testing system for hepatitis C patients.

The pharmaceuticals firm has granted a non-exclusive licence to Laboratory Corporation of America to commercialise a new test which detects IL-28B polymorphisms in patients.

This polymorphism has been associated with successful response to peginterferon alpha-based therapy, which means the test could be used to identify which hepatitis patients are most likely to benefit from treatment.

Merck Sharpe and Dohme stated that this deal is the first of a number of non-exclusive licences it intends to award to diagnostic firms.

Roger Pomerantz, global franchise lead for infectious diseases and senior vice-president at Merck Research Laboratories, said: “Viral hepatitis remains a key focus at Merck and we are committed to seeking solutions that advance patient care, including treatment approaches that are tailored to patient response.”

Earlier this month, Merck Sharpe and Dohme published data from a new survey of Aids patients in Europe, revealing that UK sufferers are among the most educated on treatment-related issues in the continent.ADNFCR-8000103-ID-800007133-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.